Ok Biotech Co Ltd
OK Biotech Co., Ltd. develops, manufactures, markets, and sells blood glucose monitoring systems and homecare healthcare devices in Taiwan and internationally. It also offers OTC hearing aids, multi-frequency therapy devices, and factory setup solutions. The company was founded in 2004 and is based in Hsinchu City, Taiwan.
Ok Biotech Co Ltd (4155) - Net Assets
Latest net assets as of September 2025: NT$2.52 Billion TWD
Based on the latest financial reports, Ok Biotech Co Ltd (4155) has net assets worth NT$2.52 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.89 Billion) and total liabilities (NT$1.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$2.52 Billion |
| % of Total Assets | 64.76% |
| Annual Growth Rate | 22.57% |
| 5-Year Change | 47.6% |
| 10-Year Change | 170.16% |
| Growth Volatility | 23.58 |
Ok Biotech Co Ltd - Net Assets Trend (2009–2024)
This chart illustrates how Ok Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ok Biotech Co Ltd (2009–2024)
The table below shows the annual net assets of Ok Biotech Co Ltd from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$2.57 Billion | +7.17% |
| 2023-12-31 | NT$2.40 Billion | +29.72% |
| 2022-12-31 | NT$1.85 Billion | +8.42% |
| 2021-12-31 | NT$1.70 Billion | -2.08% |
| 2020-12-31 | NT$1.74 Billion | +33.57% |
| 2019-12-31 | NT$1.30 Billion | +2.69% |
| 2018-12-31 | NT$1.27 Billion | +5.14% |
| 2017-12-31 | NT$1.21 Billion | +27.65% |
| 2016-12-31 | NT$944.80 Million | -0.56% |
| 2015-12-31 | NT$950.15 Million | +11.85% |
| 2014-12-31 | NT$849.48 Million | +39.34% |
| 2013-12-31 | NT$609.65 Million | +34.85% |
| 2012-12-31 | NT$452.10 Million | +49.15% |
| 2011-12-31 | NT$303.11 Million | +31.34% |
| 2010-12-31 | NT$230.78 Million | +90.34% |
| 2009-12-31 | NT$121.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ok Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 112.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$87.63 Million | 3.52% |
| Common Stock | NT$1.47 Billion | 59.01% |
| Other Comprehensive Income | NT$107.23 Million | 4.30% |
| Other Components | NT$826.62 Million | 33.17% |
| Total Equity | NT$2.49 Billion | 100.00% |
Ok Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Ok Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hai Phong Hoang Ha Paper JSC
VN:HHP
|
$44.62 Million |
|
INTRED S.P.A.
F:M7P
|
$44.63 Million |
|
Doxa AB
ST:DOXA
|
$44.63 Million |
|
Blackboxstocks Inc
NASDAQ:BLBX
|
$44.64 Million |
|
Kunyue Development Co Ltd
TWO:5206
|
$44.60 Million |
|
Twinhead International Corp
TW:2364
|
$44.59 Million |
|
Precision System Science Co. Ltd.
PINK:PCNEF
|
$44.57 Million |
|
Southeastern Banking Corp
PINK:SEBC
|
$44.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ok Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,397,849,000 to 2,492,073,000, a change of 94,224,000 (3.9%).
- Net income of 93,975,000 contributed positively to equity growth.
- Dividend payments of 44,118,000 reduced retained earnings.
- Other comprehensive income increased equity by 23,909,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$93.97 Million | +3.77% |
| Dividends Paid | NT$44.12 Million | -1.77% |
| Other Comprehensive Income | NT$23.91 Million | +0.96% |
| Other Changes | NT$20.46 Million | +0.82% |
| Total Change | NT$- | 3.93% |
Book Value vs Market Value Analysis
This analysis compares Ok Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.89x to 0.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$4.71 | NT$13.60 | x |
| 2010-12-31 | NT$6.14 | NT$13.60 | x |
| 2011-12-31 | NT$8.20 | NT$13.60 | x |
| 2012-12-31 | NT$9.66 | NT$13.60 | x |
| 2013-12-31 | NT$12.07 | NT$13.60 | x |
| 2014-12-31 | NT$13.04 | NT$13.60 | x |
| 2015-12-31 | NT$14.01 | NT$13.60 | x |
| 2016-12-31 | NT$13.86 | NT$13.60 | x |
| 2017-12-31 | NT$17.29 | NT$13.60 | x |
| 2018-12-31 | NT$15.80 | NT$13.60 | x |
| 2019-12-31 | NT$14.45 | NT$13.60 | x |
| 2020-12-31 | NT$17.06 | NT$13.60 | x |
| 2021-12-31 | NT$14.16 | NT$13.60 | x |
| 2022-12-31 | NT$13.93 | NT$13.60 | x |
| 2023-12-31 | NT$18.67 | NT$13.60 | x |
| 2024-12-31 | NT$17.02 | NT$13.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ok Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.63%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.48x
- Recent ROE (3.77%) is below the historical average (13.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 40.99% | 17.70% | 1.37x | 1.69x | NT$37.57 Million |
| 2010 | 16.35% | 9.29% | 1.25x | 1.41x | NT$14.66 Million |
| 2011 | 23.87% | 14.39% | 1.03x | 1.60x | NT$42.03 Million |
| 2012 | 21.38% | 14.72% | 0.84x | 1.72x | NT$51.47 Million |
| 2013 | 22.67% | 12.86% | 0.74x | 2.39x | NT$77.24 Million |
| 2014 | 8.40% | 11.26% | 0.45x | 1.66x | NT$-13.58 Million |
| 2015 | 11.68% | 12.96% | 0.59x | 1.52x | NT$15.95 Million |
| 2016 | 9.02% | 8.19% | 0.70x | 1.58x | NT$-9.28 Million |
| 2017 | 10.51% | 10.28% | 0.65x | 1.56x | NT$6.21 Million |
| 2018 | 12.93% | 14.40% | 0.61x | 1.48x | NT$36.52 Million |
| 2019 | 9.75% | 10.13% | 0.56x | 1.72x | NT$-3.27 Million |
| 2020 | 7.50% | 8.74% | 0.59x | 1.47x | NT$-43.13 Million |
| 2021 | 1.84% | 2.49% | 0.45x | 1.65x | NT$-139.03 Million |
| 2022 | 7.78% | 9.67% | 0.48x | 1.66x | NT$-41.00 Million |
| 2023 | 0.12% | 0.25% | 0.39x | 1.28x | NT$-236.84 Million |
| 2024 | 3.77% | 5.63% | 0.45x | 1.48x | NT$-155.23 Million |
Industry Comparison
This section compares Ok Biotech Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,271,117,333
- Average return on equity (ROE) among peers: 6.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ok Biotech Co Ltd (4155) | NT$2.52 Billion | 40.99% | 0.54x | $44.61 Million |
| Health & Life Co., Ltd. (1781) | $372.58 Million | -4.71% | 1.15x | $12.97 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.65 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.33 Billion | 1.93% | 1.30x | $38.32 Million |
| United Orthopedic (4129) | $1.77 Billion | 7.55% | 0.46x | $300.33 Million |
| Dynamic Medical Technologies (4138) | $1.76 Billion | 11.67% | 0.71x | $39.41 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $30.42 Million |
| EPS Bio Technology Corp. (4183) | $309.15 Million | 10.25% | 0.77x | $4.27 Million |